Related Experiment Video

Updated: Jul 10, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Major congenital anomalies place extremely low birth weight infants at higher risk for poor growth and developmental

Rachel V Walden1, Sarah C Taylor, Nellie I Hansen

  • 1Pediatrix Medical Group of Dallas, Richardson, Texas, USA.

Pediatrics
|November 7, 2007
PubMed

Insights

Extremely low birth weight infants with major congenital anomalies face significantly higher risks for neurodevelopmental impairment and poor growth. These infants also experience over three times the risk of rehospitalization compared to peers without anomalies.

Area of Science:

  • Neonatal Research
  • Pediatric Development
  • Congenital Anomaly Studies

Background:

  • Limited outcome data exists for extremely low birth weight (ELBW) infants with major congenital anomalies.
  • Existing studies often exclude these vulnerable infants, hindering understanding of their growth and neurodevelopmental trajectories.

Purpose of the Study:

  • To compare growth and neurodevelopmental outcomes in ELBW infants with and without major anomalies.
  • To hypothesize that infants with severe anomalies would exhibit worse growth, neurodevelopmental, and survival outcomes.

Main Methods:

  • A retrospective cohort analysis of 5920 ELBW infants surviving beyond 12 hours of life (1998-2001) across 19 neonatal network centers.
  • Neurodevelopmental and anthropometric evaluations were conducted at 18-22 months corrected age for 3705 children.
  • Statistical analysis included Wilcoxon tests, chi2/Fisher's exact tests, and regression models to adjust for confounders.

Main Results:

  • Infants with major congenital anomalies showed higher rates of neurodevelopmental impairment (Bayley MDI/PDI < 70), moderate-to-severe cerebral palsy, and smaller length and head circumference (< 10th percentile).
  • These infants experienced more rehospitalizations and increased use of early intervention services.
  • Major anomalies were associated with increased mortality before 18-22 months corrected age.

Conclusions:

  • ELBW infants with major anomalies have nearly double the risk of neurodevelopmental impairment and significantly increased risks of poor growth and rehospitalization.
  • Findings underscore the need for targeted support and intervention services for this high-risk population.
  • This data is crucial for parental counseling regarding infant outcomes.
Abstract

More Related Videos

A Rat Model of Mild Intrauterine Hypoperfusion with Microcoil Stenosis06:19

A Rat Model of Mild Intrauterine Hypoperfusion with Microcoil Stenosis

Published on: January 7, 2018

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Neurulation01:30

Neurulation

Neurulation is the embryological process which forms the precursors of the central nervous system and occurs after gastrulation has established the three primary cell layers of the embryo: ectoderm, mesoderm, and endoderm. In humans, the majority of this system is formed via primary neurulation, in which the central portion of the ectoderm—originally appearing as a flat sheet of cells—folds upwards and inwards, sealing off to form a hollow neural tube. As development proceeds, the anterior...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...